Arrowhead Research Corporation (ARWR) : Traders are bullish on Arrowhead Research Corporation (ARWR) as it has outperformed the S&P 500 by a wide margin of 3.35% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.63%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.8% in the last 1 week, and is up 2.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.36% and the 50-Day Moving Average is 10.02%.The 200 Day SMA reached 33.36%
Arrowhead Research Corporation (NASDAQ:ARWR): After opening at $7.57, the stock dipped to an intraday low of $7.25 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $7.72 and the buying power remained strong till the end. The stock closed at $7.35 for the day, a gain of 0.68% for the day session. The total traded volume was 1,762,686. The stocks close on the previous trading day was $7.35.
Arrowhead Research Corporation (ARWR) : 6 Wall Street analysts covering Arrowhead Research Corporation (ARWR) believe that the average level the stock could reach for the short term is $11.25. The maximum price target given is $15 and the minimum target for short term is around $6, hence the standard deviation is calculated at $3.6.
Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Companys therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Companys drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.